Socio-economic inequalities in the use of drugs for the treatment of chronic diseases in Italy.
Adherence
Deprivation index
Drug utilization
Persistence
Pharmacoequity
Socio-economic inequalities
Journal
International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692
Informations de publication
Date de publication:
09 11 2022
09 11 2022
Historique:
received:
13
07
2022
accepted:
03
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Since the use of medicines is strongly correlated to population health needs, higher drug consumption is expected in socio-economical deprived areas. However, no systematic study investigated the relationship between medications use in the treatment of chronic diseases and the socioeconomic position of patients. The purpose of the study is to provide a description, both at national level and with geographical detail, of the use of medicines, in terms of consumption, adherence and persistence, for the treatment of major chronic diseases in groups of population with different level of socioeconomic position. METHODS: A cross-sectional study design was used to define the "prevalent" users during 2018. A longitudinal cohort study design was performed for each chronic disease in new drug users, in 2018 and the following year. A retrospective population-based study, considering all adult Italian residents (i.e. around 50.7 million people aged ≥ 18 years). Different medications were used as a proxy for underlying chronic diseases: hypertension, dyslipidemia, osteoporosis, diabetes and chronic obstructive pulmonary disease. Only "chronic" patients who had at least 2 prescriptions within the same subgroup of drugs or specific medications during the year were selected for the analysis. A multidimensional measures of socio-economic position, declined in a national deprivation index at the municipality level, was used to identify and estimate the relationship with drug use indicators. The medicine consumption rate for each pharmacological category was estimated for prevalent users while adherence and persistence to pharmacologic therapy at 12 months were evaluated for new users. The results highlighted how the socioeconomic deprivation is strongly correlated with the use of medicines: after adjustment by deprivation index, the drug consumption rates decreased, mainly in the most disadvantaged areas, where consumption levels are on average higher than in other areas. On the other hand, the adherence and persistence indicators did not show the same trend. This study showed that drug consumption is influenced by the level of deprivation consistently with the distribution of diseases. For this reason, the main levers on which it is necessary to act to reduce disparities in health status are mainly related to prevention. Moreover, it is worth pointing out that the use of a municipal deprivation indicator necessarily generates an ecological bias, however, the experience of the present study, which for the first-time deals with the complex and delicate issue of equity in Italian pharmaceutical assistance, sets the stage for new insights that could overcome the limits.
Sections du résumé
BACKGROUND
Since the use of medicines is strongly correlated to population health needs, higher drug consumption is expected in socio-economical deprived areas. However, no systematic study investigated the relationship between medications use in the treatment of chronic diseases and the socioeconomic position of patients. The purpose of the study is to provide a description, both at national level and with geographical detail, of the use of medicines, in terms of consumption, adherence and persistence, for the treatment of major chronic diseases in groups of population with different level of socioeconomic position. METHODS: A cross-sectional study design was used to define the "prevalent" users during 2018. A longitudinal cohort study design was performed for each chronic disease in new drug users, in 2018 and the following year. A retrospective population-based study, considering all adult Italian residents (i.e. around 50.7 million people aged ≥ 18 years). Different medications were used as a proxy for underlying chronic diseases: hypertension, dyslipidemia, osteoporosis, diabetes and chronic obstructive pulmonary disease. Only "chronic" patients who had at least 2 prescriptions within the same subgroup of drugs or specific medications during the year were selected for the analysis. A multidimensional measures of socio-economic position, declined in a national deprivation index at the municipality level, was used to identify and estimate the relationship with drug use indicators. The medicine consumption rate for each pharmacological category was estimated for prevalent users while adherence and persistence to pharmacologic therapy at 12 months were evaluated for new users.
RESULTS
The results highlighted how the socioeconomic deprivation is strongly correlated with the use of medicines: after adjustment by deprivation index, the drug consumption rates decreased, mainly in the most disadvantaged areas, where consumption levels are on average higher than in other areas. On the other hand, the adherence and persistence indicators did not show the same trend.
CONCLUSIONS
This study showed that drug consumption is influenced by the level of deprivation consistently with the distribution of diseases. For this reason, the main levers on which it is necessary to act to reduce disparities in health status are mainly related to prevention. Moreover, it is worth pointing out that the use of a municipal deprivation indicator necessarily generates an ecological bias, however, the experience of the present study, which for the first-time deals with the complex and delicate issue of equity in Italian pharmaceutical assistance, sets the stage for new insights that could overcome the limits.
Identifiants
pubmed: 36352409
doi: 10.1186/s12939-022-01772-8
pii: 10.1186/s12939-022-01772-8
pmc: PMC9644599
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
Hypertens Res. 2021 May;44(5):550-560
pubmed: 33442029
Epidemiol Prev. 2020 Mar-Jun;44(2-3):162-170
pubmed: 32631016
Nutr Metab Cardiovasc Dis. 2020 Aug 28;30(9):1525-1534
pubmed: 32580888
Eur Heart J Suppl. 2017 May;19(Suppl D):D3-D54
pubmed: 28751833
J Hum Hypertens. 2009 Apr;23(4):238-44
pubmed: 18668127
Clinicoecon Outcomes Res. 2018 May 03;10:251-258
pubmed: 29765241
Epidemiol Prev. 2011 Jan-Feb;35(1):59
pubmed: 21436498
Epidemiol Prev. 2010 Jul-Aug;34(4):167-76
pubmed: 21224518
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 1):172-178
pubmed: 33415960
BMJ Open. 2016 Apr 04;6(4):e010926
pubmed: 27044584
Epidemiol Prev. 2019 Jan-Feb;43(1S1):1-120
pubmed: 30808126
Int J Health Serv. 1983;13(3):433-42
pubmed: 6411632
Respir Med. 2016 Oct;119:160-167
pubmed: 27692139
Nutr Metab Cardiovasc Dis. 2018 Mar;28(3):219-225
pubmed: 29337018
Syst Rev. 2019 May 10;8(1):112
pubmed: 31077247
Osteoporos Int. 2018 Dec;29(12):2623-2637
pubmed: 30417253
Health Serv Manage Res. 2021 Aug;34(3):136-147
pubmed: 32475173
Curr Diabetes Rev. 2011 May;7(3):148-58
pubmed: 21418003
Value Health. 2014 Mar;17(2):288-96
pubmed: 24636389
BMC Int Health Hum Rights. 2015 Feb 07;15:2
pubmed: 25881154
JAMA. 2021 Nov 9;326(18):1793-1794
pubmed: 34677579
Health Policy. 2018 Apr;122(4):334-351
pubmed: 29373188
Ital J Pediatr. 2021 Jun 24;47(1):139
pubmed: 34167569
Osteoporos Int. 2019 Aug;30(8):1627-1634
pubmed: 31089764
J Clin Pharm Ther. 2012 Feb;37(1):37-44
pubmed: 21294760
Int J Chron Obstruct Pulmon Dis. 2018 Feb 26;13:695-702
pubmed: 29520137
Eur J Clin Pharmacol. 2014 Mar;70(3):331-7
pubmed: 24309838
Popul Health Metr. 2018 Apr 12;16(1):7
pubmed: 29650013
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):867-871
pubmed: 29952045
Epidemiol Prev. 2011 Sep-Dec;35(5-6 Suppl 4):174-80
pubmed: 22166298